What do systematic reviews say?

Fibrin‐based haemostatic agents vs placebo or no intervention

It is very uncertain whether fibrin‐based haemostatic agents changes postoperative transfusion Median compared with no intervention or placebo (very low certainty).

• Fibrin‐based haemostatic agents for reducing blood loss in adult liver resection 2023 · Cochrane Headline outcomes only
  RR 1.04 [0.77, 1.4]
  5 studies · 864 participants
  Very low

Fibrin‐based haemostatic agents vs placebo or no intervention

It is very uncertain whether fibrin‐based haemostatic agents changes reoperation Median compared with no intervention or placebo (very low certainty).

• Fibrin‐based haemostatic agents for reducing blood loss in adult liver resection 2023 · Cochrane Headline outcomes only
  RR 2.92 [0.58, 14.61]
  2 studies · 612 participants
  Very low

Fibrin‐based haemostatic agents vs placebo or no intervention

It is very uncertain whether fibrin‐based haemostatic agents changes postoperative bile leak Median compared with no intervention or placebo (very low certainty).

• Fibrin‐based haemostatic agents for reducing blood loss in adult liver resection 2023 · Cochrane Headline outcomes only
  RR 1 [0.67, 1.48]
  4 studies · 782 participants
  Very low

Perampanel add‐on vs placebo

Perampanel add‐on leads to higher ≥ 50% reduction in seizure frequency compared with placebo (high certainty).

• Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
  RR 1.67 [1.43, 1.95]
  7 studies · 2524 participants
  High

Perampanel add‐on vs placebo

Perampanel add‐on may leads to higher seizure freedom compared with placebo (low certainty).

• Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
  RR 2.5 [1.38, 4.54]
  5 studies · 2323 participants
  Low

Perampanel add‐on vs placebo

Perampanel add‐on may leads to higher treatment withdrawal due to any reason compared with placebo (low certainty).

• Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
  RR 1.3 [1.03, 1.63]
  7 studies · 2524 participants
  Low

Perampanel add‐on vs placebo

Perampanel add‐on may leads to higher treatment withdrawal due to adverse effects compared with placebo (low certainty).

• Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
  RR 2.36 [1.59, 3.51]
  7 studies · 2524 participants
  Low

Perampanel add‐on vs placebo

Perampanel add‐on leads to higher proportion of participants who experienced ≥ 1 adverse effect compared with placebo (high certainty).

• Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
  RR 1.17 [1.1, 1.24]
  7 studies · 2524 participants
  High

Perampanel add‐on vs placebo

Perampanel add‐on may leads to higher proportion of participants who experienced ataxia compared with placebo (low certainty).

• Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
  RR 14.32
  2 studies · 1098 participants
  Low

Perampanel add‐on vs placebo

Perampanel add‐on may leads to higher proportion of participants who experienced dizziness compared with placebo (low certainty).

• Perampanel add‐on for drug‐resistant focal epilepsy 2023 · Cochrane Headline outcomes only
  RR 2.87
  7 studies · 2524 participants
  Low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 147 participants
  Low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1108 participants
  High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1061 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1139 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1134 participants
  High